|
LLGL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
9.580800E-03 |
| Normal-vs-Stage3 |
2.51454412847352E-12 |
| Normal-vs-Stage4 |
7.84279974297419E-10 |
| Stage1-vs-Stage2 |
7.041600E-02 |
| Stage1-vs-Stage3 |
4.367400E-01 |
| Stage1-vs-Stage4 |
6.193800E-01 |
| Stage2-vs-Stage3 |
3.339600E-02 |
| Stage2-vs-Stage4 |
6.750200E-02 |
| Stage3-vs-Stage4 |
8.372400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.800190E-04 |
| Normal-vs-Asian |
6.41270003765015E-09 |
| Caucasian-vs-AfricanAmerican |
7.894000E-01 |
| Caucasian-vs-Asian |
3.568800E-01 |
| AfricanAmerican-vs-Asian |
7.127600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.00920050094544E-10 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.061990E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.7715611723761E-16 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.43379999983928E-07 |
| Normal-vs-Age(81-100Yrs) |
2.222300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.271200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.226200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.590400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.449800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.388600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.010600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.525220E-01 |
| Classical-VS-Follicular |
1.62436730732907E-12 |
| Classical-VS-Other |
8.954100E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.95874436062604E-13 |
| Tall-VS-Other |
1.857930E-02 |
| Tall-VS-Normal |
3.10160008787363E-10 |
| Follicular-VS-Other |
1.193380E-01 |
| Follicular-VS-Normal |
4.337800E-01 |
| Other-VS-Normal |
3.132000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.91800020310495E-10 |
| Normal-vs-N1 |
1.56528999999406E-05 |
| N0-vs-N1 |
5.484200E-01 |
|
|
